Suggestions
Jeff Huber
Professional information not available
Jeff Huber is a prominent technology executive and entrepreneur with extensive experience in the tech and healthcare industries. He is the Co-Founder and President of OpenCovidScreen, a non-profit organization focused on catalyzing innovation in COVID-19 testing and screening.12
Some key highlights about Jeff Huber:
Professional Background
- Co-Founder & General Partner of Triatomic Capital, a venture capital firm (2022-present)3
- Founding CEO and Vice Chairman of GRAIL, a cancer diagnostic company (2016-2021)23
- Senior Vice President at Google (2003-2016), where he:
- Co-founded Google's life sciences efforts in Google[x] (2013-2016)
- Led development for Google Maps (2011-2013)
- Led development for Google Apps (2005-2010)
- Led development for Google Ads (2003-2011)3
Education
- Bachelor's degree in computer engineering from the University of Illinois23
- Master's degree in business from Harvard University23
- Visiting Scholar in Stanford University's Department of BioEngineering (2017-2020)3
Board Memberships and Advisory Roles
Jeff serves on the boards of several companies and organizations, including:
- Mammoth Biosciences
- Electronic Arts (EA)
- Upstart (UPST)
- Zapata Computing
- Parker Institute for Cancer Immunotherapy (PICI)3
He is also an advisory board member for Stanford's Precision Health and Integrated Diagnostics Center (PHIND) and Duke University's Research Translation & Commercialization (RTC) Council.3
Achievements and Recognition
- Recognized as one of the '100 Most Intriguing Entrepreneurs' (2017)3
- Received a 'Distinguished Alumni Award' from the University of Illinois College of Electrical & Computer Engineering (2018)34
Jeff Huber's LinkedIn username is indeed jeffhuber, as mentioned in the query.3
Highlights
Big steps towards achieving the mission to 'detect cancer early, when it can be cured.' HUGE congrats to the GRAIL @GRAILBio Team! –
"The results are remarkable. PATHFINDER 2 reported that: ► Seven times more cancers were detected when Galleri was added to US recommended screening for breast, cervical, colorectal, and lung cancers.
► More than half of the Galleri detected cancers in this study were found in early stages, when cancers are more treatable and potentially curable.
► Approximately three-quarters of the cancers detected by Galleri do not have standard-of-care screening options in the US."
Get it at: https://t.co/Uyr3eUEAVo
AI-based protein design isn't about more data – it's about the right data at scale.
@ManifoldBio's 100,000X high-throughput in-vivo platform generates scaled biological data that powers gen AI to design 1st-in-class therapeutics that actually work in-life.
Very worth a watch:
